The constitutive androstane receptor activator 4‐[(4R,6R)‐4,6‐diphenyl‐1,3‐dioxan‐2‐yl]‐N,N‐dimethylaniline inhibits the gluconeogenic genes PEPCK and G6Pase through the suppression of HNF4α and FOXO1 transcriptional activity

• Published in: British journal of pharmacology Vol. 168; no. 8; pp. 1923 - 1932
• Main Authors: Yarushkin, AA, Kachaylo, EM, Pustylnyak, VO
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.04.2013
• Subjects: Aniline Compounds - pharmacology; Animals; CAR; Diet, High-Fat; Forkhead Transcription Factors - metabolism; FOXO1; G6Pase; Gene Expression - drug effects; Gene Expression Regulation; gluconeogenesis; Gluconeogenesis - drug effects; Glucose - administration & dosage; Glucose Tolerance Test; Glucose-6-Phosphatase - genetics; Glucose-6-Phosphatase - metabolism; Hepatocyte Nuclear Factor 4 - metabolism; Heterocyclic Compounds, 1-Ring - pharmacology; HNF4α; Insulin - administration & dosage; Intracellular Signaling Peptides and Proteins - genetics; Intracellular Signaling Peptides and Proteins - metabolism; Liver - metabolism; Male; Nerve Tissue Proteins - metabolism; PEPCK; Phosphoenolpyruvate Carboxykinase (GTP) - genetics; Phosphoenolpyruvate Carboxykinase (GTP) - metabolism; Promoter Regions, Genetic; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear - agonists; Receptors, Cytoplasmic and Nuclear - genetics; Receptors, Cytoplasmic and Nuclear - metabolism; Research Papers
• ISSN: 0007-1188; 1476-5381
• DOI: 10.1111/bph.12090

Background and Purpose The dual role of the constitutive androstane receptor (CAR) as both a xenosensor and a regulator of endogenous energy metabolism (lipogenesis and gluconeogenesis) has recently gained acceptance. Here, we investigated the effects of 4‐[(4R,6R)‐4,6‐diphenyl‐1,3‐dioxan‐2‐yl]‐N,N‐dimethylaniline (transpDMA), an effective CAR activator, on the gluconeogenic genes phosphoenolpyruvate carboxykinase (PEPCK) and glucose‐6‐phosphatase (G6Pase) in rat livers. Experimental Approach The effects of transpDMA were investigated in normal and high‐fat diet‐fed Wistar rats using real‐time PCR, Western blotting, chromatin immunoprecipitation assays (ChIP), glucose tolerance test and insulin tolerance test. Key Results The expression of the gluconeogenic enzymes PEPCK and G6Pase was repressed by transpDMA treatment under fasting conditions. Long‐term CAR activation by transpDMA significantly reduced fasting blood glucose levels and improved glucose homeostasis and insulin sensitivity in high‐fat diet‐fed rats. The metabolic benefits of CAR activation by transpDMA may have resulted from the inhibition of hepatic gluconeogenic genes. ChIP assays demonstrated that transpDMA prevented the binding of forkhead box O1 (FOXO1) to insulin response sequences in the PEPCK and G6Pase gene promoters in rat livers. Moreover, transpDMA‐activated CAR inhibited hepatocyte nuclear factor‐4α (HNF4α) transactivation by competing with HNF4α for binding to the specific binding element (DR1‐site) in the gluconeogenic gene promoters. Conclusions and Implications Our results provide evidence to support the conclusion that transpDMA inhibits the gluconeogenic genes PEPCK and G6Pase through suppression of HNF4α and FOXO1 transcriptional activity.